The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

Brachytherapy, a form of internal radiotherapy, has emerged as a promising treatment modality for patients with non-small cell lung cancer (NSCLC). This technique involves the precise implantation of ...

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

In new research, a team led by University of Cincinnati researchers has identified a potential new way to make radiation more effective and improve outcomes for patients with lung cancer that has ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

Tecentriq with chemoradiation improved long-term quality of life in limited-stage small cell lung cancer without increasing fatigue. Twice-daily radiation showed better survival and quality of life ...

Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...

About 80% of people who have lung cancer have non-small-cell lung cancer. NSCLC usually spreads more slowly than small-cell lung cancers. Both cancers affect the lungs and have similar symptoms, but ...

Early-stage non-small cell lung cancer (NSCLC) offers a better prognosis than advanced stages. Staging helps inform treatment by describing your cancer's size, lymph node involvement, and metastasis.

If you or a loved one has lung cancer, you may be interested in learning more about medicines used to treat it. One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy ...